Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC).

被引：3
|
作者：
Rose, Tracy L. [1 ,2 ]
Harrison, Michael Roger [3 ]
Deal, Allison Mary [2 ]
Osterman, Chelsea K. [4 ]
Ramalingam, Sundhar [5 ]
Whang, Young E. [6 ]
Brower, Blaine Y. [7 ]
Bjurlin, Marc [6 ]
Smith, Angela B. [6 ]
Nielsen, Matthew E. [6 ]
Tan, Hung-Jui [6 ]
Wallen, Eric M. [6 ]
George, Daniel J. [3 ]
Zhang, Tian [3 ]
Drier, Anthony [6 ]
Kim, William Y. [2 ]
Milowsky, Matthew, I [7 ]
机构：
[1] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA
[2] UNC, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA
[3] Duke Univ, Duke Canc Inst, Ctr Prostate & Urol Canc, Durham, NC USA
[4] Univ N Carolina, Dept Med, Div Oncol, Chapel Hill, NC 27515 USA
[5] Duke Canc Inst, Durham, NC USA
[6] Univ N Carolina, Chapel Hill, NC 27515 USA
[7] Univ N Carolina, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27515 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.396
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
396
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Neoadjuvant nivolumab, gemcitabine and cisplatin in muscle-invasive bladder cancer: Study update
    Gupta, Shilpa
    Weight, Christopher J.
    Agarwal, Neeraj
    Gupta, Sumati
    Konety, Badrinath
    Gibb, Ewan
    Davicioni, Elai
    Thyagarajan, Bharat
    Sonpavde, Guru
    [J]. CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [42] The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy
    Murasawa, Hiromi
    Koie, Takuya
    Ohyama, Chikara
    Yamamoto, Hayato
    Imai, Atsushi
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Iwabuchi, Ikuya
    Ogasawara, Masaru
    Kawaguchi, Toshiaki
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (01) : 159 - 165
  • [43] The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy
    Hiromi Murasawa
    Takuya Koie
    Chikara Ohyama
    Hayato Yamamoto
    Atsushi Imai
    Shingo Hatakeyama
    Takahiro Yoneyama
    Yasuhiro Hashimoto
    Ikuya Iwabuchi
    Masaru Ogasawara
    Toshiaki Kawaguchi
    [J]. International Journal of Clinical Oncology, 2017, 22 : 159 - 165
  • [44] Assessment of sarcopenia as predictor of response and outcome after neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC).
    Grivas, Petros
    Zargar, Homi
    Ercole, Cesar Emilio
    Kovac, Evan
    Remer, Erick M.
    Karim, Wadih
    Emamekhoo, Hamid
    Stephenson, Andrew J.
    Fergany, Amr Farouk
    Gong, Michael C.
    Campbell, Steven C.
    Berglund, Ryan Kent
    Dreicer, Robert
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Neoadjuvant sintilimab combined with gemcitabine and cisplatin (GP) for muscle-invasive bladder cancer (MIBC) patients followed by selective bladder sparing surgery
    Tong, Z.
    Fu, G.
    Zhou, F.
    Liu, X.
    Xue, X.
    Zhang, H.
    Wang, Y.
    Zhu, X.
    Gao, Y.
    Liu, L.
    Bao, X.
    Zheng, Y.
    Fang, W.
    Zhao, P.
    Jin, B.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1210 - S1210
  • [46] A phase II clinical trial of toripalimab combined with cisplatin plus gemcitabine chemotherapy as neoadjuvant treatment for muscle-invasive bladder cancer
    Yang, Rong
    Li, Tianhang
    Zhang, Shun
    Zhang, Shiwei
    Guo, Hongqian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] A phase II study of neoadjuvant erlotinib (Tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Preliminary results
    Smith, Angela
    Coward, Matthew
    Kim, William
    Nielsen, Matthew
    Wallen, Eric
    Pruthi, Raj S.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2009, 209 (03) : S129 - S129
  • [48] A phase II study of neoadjuvant erlotinib (tarceva) in patients with muscle-invasive bladder cancer undergoing radical cystectomy: Preliminary results
    Pearson, Matthew
    Nix, Jeffrey
    Kim, William
    Grigson, Gayle
    Wallen, Eric
    Pruthi, Raj S.
    [J]. JOURNAL OF UROLOGY, 2008, 179 (04): : 119 - 119
  • [49] Radical Cystectomy (RC) Versus Bladder Preservation Therapy (BPT) for Muscle-invasive Bladder Cancer
    Bekelman, J. E.
    Handorf, E.
    Guzzo, T.
    Christodouleas, J.
    Resnick, M.
    Swisher-McClure, S.
    Vaughn, D.
    Pollack, C.
    Polsky, D.
    Mitra, N.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S120 - S121
  • [50] Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
    Galsky, Matthew D.
    Pal, Sumanta K.
    Chowdhury, Simon
    Harshman, Lauren C.
    Crabb, Simon J.
    Wong, Yu-Ning
    Yu, Evan Y.
    Powles, Thomas
    Moshier, Erin L.
    Ladoire, Sylvain
    Hussain, Syed A.
    Agarwal, Neeraj
    Vaishampayan, Ulka N.
    Recine, Federica
    Berthold, Dominik
    Necchi, Andrea
    Theodore, Christine
    Milowsky, Matthew I.
    Bellmunt, Joaquim
    Rosenberg, Jonathan E.
    [J]. CANCER, 2015, 121 (15) : 2586 - 2593
12345